ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug. The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug. The agency said it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the product can lower a person's heart rate temporarily. As for the patient's death, the FDA said an exact cause of death couldn't be identified. The FDA said the patient had extensive brainstem MS lesions, which also have been associated with sudden death. The FDA also said it looked at other deaths that appeared to be from cardiovascular causes in patients who had been taking Gilenya and concluded that the drug's "contribution to the death was unclear." The FDA said the drug shouldn't be used in patients who have had a stroke or heart trouble within the past six months. The agency also said the drug shouldn't be used in patients taking some kinds of antiarrhythmic heart medicines. -By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
01/28/201513:45:10EU Approves Three-Part Deal Between Novartis, GlaxoSmithKline
01/27/201517:37:33ADR Shares End Mixed; Philips Shares Drop
01/27/201513:31:53Zurich Stocks Enjoy Gains -- Market Talk
01/27/201513:23:40Novartis Upbeat Despite Weaker Profit -- 2nd Update
01/27/201513:16:43EUROPE MARKETS: Philips, Siemens Shares Weigh On European Markets
01/27/201504:42:08Novartis Upbeat Despite Weaker Profit -- Update
01/27/201502:43:04Novartis Posts Fall in Fourth-Quarter Profit
01/22/201510:31:06Novartis 4Q Profit May Drop -- Earnings Preview
01/22/201510:01:33Novartis 4Q 2014 -- Forecast
01/20/201517:13:11Supreme Court Sides With Teva in Patent Case on Copaxone -- 2nd...
01/20/201512:59:54Supreme Court Sides With Teva in Patent Case on Copaxone -- Update
01/20/201511:02:18Supreme Court Sides With Teva in Patent Case on Copaxone
01/19/201507:30:12Novartis Wins European Approval for Skin Remedy Cosentyx
01/19/201506:22:23EUROPE MARKETS: European Stocks Edge Higher, But Oil Shares Underperform
01/15/201511:56:52Swiss Businesses Fear Franc's Strength --Update
01/15/201510:50:32Swiss Businesses Fear Impact of Central Bank's Franc Move
01/08/201503:12:33Novartis Applies for U.S. Approval for Lung Disease Drugs
01/07/201508:30:09Eli Lilly 2015 Outlook Falls Below Expectations
01/06/201511:20:20India Shares Post Biggest Percentage Decline in 16 Months
01/01/201503:21:24Novartis Completes Sale of Animal Health Division to Eli Lilly

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad